Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An update from Cytek Biosciences (CTKB) is now available.
Cytek Biosciences, Inc. has announced a shift in its financial leadership, with Patrik Jeanmonod transitioning from Chief Financial Officer to Head of Corporate Development Analytics, effective March 17, 2024. Following Jeanmonod’s role change, William McCombe will take over as the new CFO starting March 18, 2024. McCombe, with a wealth of experience from notable firms such as Pixxel Space Technologies and Velo3D Inc., will receive a base salary of $420,000, along with the potential for a 50% bonus, and equity grants valued at $1,250,000. His compensation package includes both stock options and restricted stock units, with a structured vesting schedule tied to continued service at the company.
For detailed information about CTKB stock, go to TipRanks’ Stock Analysis page.
